WASHINGTON (AP) — U.S. regulators will begin offering faster reviews to new medicines that administration officials deem as promoting “the health interests of Americans,” under a new initiative announced Tuesday.
FDA to offer faster drug reviews to companies promoting ‘national priorities’
